 Aileron Therapeutics ALRN, the clinical-stage leader in the field of stabilized, cell-permeating peptides, presented new data at the 2019 AACR-NCI-EORTC Conference from nonclinical studies in which ALRN-6924, a dual inhibitor of MDM2 and MDMX, prevented chemotherapy-related toxicities in cellular studies and mouse models of cancer without limiting and even enhancing anti-cancer efficacy. Chemotherapy is widely used to treat and often cure millions of cancer patients each year, but chemotherapy is toxic and commonly causes severe or life-threatening side effects, said Dr. Manuel Aivado, President and CEO of Aileron Therapeutics. 